A P R I L 2 0 0 1 73 Oxidative DNA damage generated by an attack of reactive oxygen species causes mutation or cell death that may lead to various diseases and may be related to initiation or progression of carcinogenesis. 8-Oxo-29 -deoxyguanosine (8-oxo-dG) is a major oxidative DNA damage product that can result in mutation, and hMTH1, human MutT homolog protein 1, has been identi ed as an enzyme that hydrolyzes 8-oxo-dGTP to the monophosphate, thus preventing accumulation of 8-oxo-dG in DNA. With immunohistochemical approaches, we investigated accumulation of 8-oxo-dG and expression of hMTH1 in brain tumor tissues obtained from surgical and autopsy cases, including 42 neuroepithelial tumors, 5 meningiomas, 2 metastatic brain tumors, and 1 schwannoma. 8-Oxo-dG accumulation and hMTH1 expression were increased in various brain tumors. Nuclei of brain tumor cells were immunoreactive for 8-oxo-dG in all cases. In most cases, both nuclei and cytoplasm of the tumor cells were immunoreactive for hMTH1. Both 8-oxo-dG accumulation and hMTH1 expression were most evident in highgrade gliomas, indicating that oxidative stress was high in these gliomas. Thus, the defense mechanism against such oxidative stress may be enhanced as well. These results suggest that oxidative stress may play a role in tumor progression. Neuro-Oncology 3, 73-81, 2001 (Posted to Neuro-Oncology [serial online], Doc. 00-058, February 20, 2001 R OS 2 are continuously arising in normal cellular metabolism, where they oxidize proteins, lipids, and nucleic acids (Fraga et al., 1990) . There are various protective mechanisms against such oxidative damage. When the balance between ROS generation and protective mechanisms is lost, oxidative stress is increased and cells are highly damaged. Oxidative DNA damage generated by ROS results in mutations that may cause various diseases, including cancer (Lee et al., 1998; Musarrat et al., 1996) . 8-Oxoguanine, an oxidized form of guanine, is a well-known marker of oxidative DNA damage, and it causes A:T to C:G or G:C to T:A transversion mutations because of its base pairing nature with adenine as well as cytosine (Maki and Sekiguchi, 1992) . It has been reported that 8-oxo-dG accumulates at higher levels in breast, renal cell, and gastric tumors than in adjacent or normal tissues (Lee et al., 1998; Musarrat et al., 1996; Okamoto et al., 1994) , indicating that there is increased oxidative stress in tumor tissues, and it may be related to initiation or progression of carcinogenesis.
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To minimize such deleterious effects of oxidative DNA damage, organisms come equipped with elaborate error-avoiding mechanisms. In Escherichia coli, there are 3 enzymes, MutM, MutY, and MutT, that are involved in avoiding errors in DNA caused by 8-oxoguanine (Maki and Sekiguchi, 1992; Michaels et al., 1992; Tchou et al., 1991) . MutM protein removes 8-oxoguanine paired with cytosine (Tchou et al., 1991) , and MutY protein removes adenine paired with 8-oxoguanine in DNA (Michaels et al., 1992) . MutT protein hydrolyzes 8-oxo-dGTP to the corresponding monophosphate, thereby preventing misincorporation of 8-oxo-dG into DNA (Akiyama et al., 1989; Maki and Sekiguchi, 1992; Sekiguchi, 1996) . Human cells possess the OGG1, MYH, and MTH1 genes, which are the human homologs of the E. coli genes mutM (Boiteux and Radicella, 1999; , mutY, (Ohtsubo et al., 2000; Slupska et al., 1996; , and mutT, respectively (Furuichi et al., 1994; Sakumi et al., 1993) .
Human MTH1 (hMTH1) protein hydrolyzes oxidized purine-nucleoside triphosphates, including not only 8-oxo-dGTP but also 2-hydroxy-dATP (Fujikawa et al., 1999; Sakumi et al., 1993) , indicating that there are various other routes of oxidative DNA damage that are also deleterious for cells. Correlation between hMTH1 expression and clinical stage has previously been discussed with regard to breast and renal cell carcinoma (Okamoto et al., 1996; Wani et al., 1998) . Furthermore, it has been suggested that hMTH1 might be a useful marker of oxidative stress and can be used to explore the relationship between oxidative stress and genomic instability (Kennedy et al., 1998) .
Accumulation of 8-oxo-dG in various tumors has been examined with immunohistochemical approaches (Kondo et al., 1999; Matsui et al., 1999) . In brain tumor tissues, expression of superoxide dismutase and nitric oxide synthase, which may increase oxidative stress, has been examined (Cobbs et al., 1995; Yoshii et al., 1999) , but there is no report on 8-oxo-dG accumulation and hMTH1 expression. In the present study, we used immunohistochemistry to examine levels of 8-oxo-dG accumulation and hMTH1 expression in brain tumor tissues and to evaluate the patterns of their occurrence in low-and high-grade tumors.
Materials and Methods

Cases
Tumor tissues were obtained at surgery from 45 patients (27 men and 18 women, ranging in age from 1 to 76 years) ( Table 1 , cases 1-45). We also investigated 5 additional brain tumors obtained by postmortem examination (1 glioblastoma, 1 anaplastic ependymoma, 1 medulloblastoma, and 2 metastatic brain tumors) together with normal brain tissues (Table 1, cases 46-50). As controls, 5 samples (3 men and 2 women, ranging in age from 47 to 79 years) of cerebral cortex without neurologic disorder were used.
Antibodies
Rabbit polyclonal antibodies against hMTH1 protein (anti-MTH1) were raised by immunizing the recombinant hMTH1d protein and were af nity-puri ed with the aid of antigen columns, as previously described (Kang et al., 1995; Kakuma et al., 1995) . A monoclonal antibody speci c for 8-oxo-dG (anti-8-oxo-dG), N45.1, was obtained from Nippon Roukaseigyo Kenkyujo (Shizuoka, Japan). The speci city of N45.1 was conrmed in previous studies (Toyokuni et al., 1997) .
Sodium Dodecyl Sulfate-Polyacrylamide Gel Eletrophoresis and Immunoblotting for hMTH1
Frozen tumor samples of an oligodendroglioma ( (Yakushiji et al., 1997) was separated by 12% sodium dodecyl sulfate-polyacrylamide gel eletrophoresis and transferred onto a polyvinylidene di uoride membrane (PVDF; Millipore, Bedford, MA). After the reaction was blocked with 5% low-fat milk in TBST, the membrane was incubated with anti-MTH1 (Kang et al., 1995; Kakuma et al., 1995) in TBST containing 5% lowfat milk at 4°C overnight. The membrane was then washed in TBST and incubated with alkaline phosphatase-conjugated antirabbit IgG antibody (1:7500 dilution, Promega, Madison, Wis.) in TBST containing 5% low-fat milk for 30 min. After the membrane was washed in TBST, the signal was visualized with CDP-Star detection reagent (Amersham, Little Chalfont, U.K.) according to the manufacturer's instruction.
Immunohistochemistry
Immunohistochemistry with N45.1 for 8-oxo-dG (1:100 dilution) or with anti-MTH1 (0.5 mg/ml) was performed on paraf n sections by the indirect immunoperoxidase method. Specimens were xed in 10% formalin and embedded in paraffin; samples were then sectioned at 5 mm. Sections were deparaf nized in xylene and hydrated in an ethanol gradient. Endogenous peroxidase activity was blocked with 0.3% H 2 O 2 in absolute methanol for 30 min at room temperature. After being rinsed in tap water, sections were completely immersed in citrate buffer and autoclaved for 10 min for immunohistochemical analysis of hMTH1. Sections were then washed in 50 mM Tris-HCl (pH 7.6), followed by overnight incubation with the primary antibodies at 4°C. After being washed again in the same buffer, sections were incubated with horseradish peroxidase-conjugated secondary antibody (1:200 dilution, Vector Laboratories, Burlingame, Calif.). The colored reaction product was developed with 3,39 -diaminobenzidine tetrahydrochloride (DAB) solution. Immunohistochemical procedures were performed in the same condition. 
Evaluation and Semiquantitative Analysis
Intensity levels of immunoreactivity were scored as follows. The OD of the 8-oxo-G and hMTH1 immunoreactions was measured for surgically removed tissues with National Institutes of Health image software version 1.6. Four separate elds of each specimen were selected, and the OD was obtained for each eld. The ODs of each case were averaged, and the rOD was obtained individually by dividing the averaged OD of a case by the maximum OD among all cases. According to the rOD, intensity levels of immunoreactivity were categorized as (0) not detectable; (1) faint (0 < rOD = 0.3); (2) moderate (0.3 < rOD = 0.7); and (3) high (0.7 < rOD = 1).
The OD of the 8-oxo-G and hMTH1 immunoreactions was also measured for autopsied tissues. Both tumor and normal cerebral cortex were selected for each case and their ODs were measured in the following manner. Four separate elds were selected and the OD was obtained for each of the 4 elds. The ODs were averaged after being corrected for background by subtracting the OD of the cerebral white matter on the same section. Statistical analysis of the difference in corrected OD value between tumor and cerebral cortex was performed using the StatView-J4.5 program (Abacus Concepts, Berkeley, Calif.) and the Wilcoxon signed-rank test. P < 0.05 was considered signi cant.
Intensity levels of immunoreactivity between highgrade and low-grade glioma were tested for statistical signi cance using the Mann-Whitney U test. P < 0.05 was considered signi cant.
Results
hMTH1 Immunoblot Analysis
The result of immunoblotting with anti-MTH1 is shown in Fig. 1 . Tissue homogenates from anaplastic ependymoma, oligodendroglioma, and glioblastoma contained hMTH1 protein detected as a distinct band migrating at 18 kDa, identical to recombinant hMTH1. Normal tissue homogenates did not contain a detectable level of hMTH1.
Immunohistochemistry for 8-Oxo-dG and hMTH1
Control cases. In 4 of 5 control cases, cerebral cortex showed faint immunoreactivity to both anti-8-oxo-dG and anti-MTH1. One case showed negative immunoreactivity to anti-8-oxo-dG and anti-MTH1.
Brain tumors from surgical cases. As summarized in Table 1 , nuclei of many tumor cells were immunoreactive to anti-8-oxo-dG in all 45 cases ( Fig. 2A, 2C , 2E, and 2G). Similarly, most of the tumor cells showed immunoreactivity to anti-MTH1 in all 45 cases. In 36 of 45 cases, both nuclei and cytoplasm were stained by anti-MTH1 (Fig. 2D, 2F , and 2H), and in the other 9, only the cytoplasm was immunoreactive (Fig. 2B) . The vascular wall within the tumor tissues showed negative or faint immunoreactivity to both anti-8-oxo-dG and anti-MTH1 (Fig. 2C and 2D ).
In cases of high-grade glioma, including glioblastoma (Fig. 2E), anaplastic astrocytoma (Fig. 2C) , anaplastic ependymoma, and anaplastic oligodendroglioma, 12 of 19 cases showed high anti-8-oxo-dG immunoreactivity. Seven of these 19 showed moderate immunoreactivity to anti-8-oxo-dG. In low-grade glioma, including astrocytoma, pilocytic astrocytoma, fibrillary astrocytoma, oligoastrocytoma ( Fig. 2A) , oligodendroglioma, subependymoma, ependymoma, and ganglioglioma, 6 of 14 showed faint, and 7 of 14 cases showed moderate immunoreactivity to the antibody.
In 6 of 19 cases of high-grade glioma, the tumors showed high immunoreactivity to anti-MTH1. Eleven of these 19 cases showed moderate immunoreactivity to anti-MTH1. In low-grade glioma, 9 of 14 cases showed faint immunoreactivity to the antibodies. The other 5 showed moderate immunoreactivity, and no case showed high immunoreactivity to anti-MTH1. Thus, high-grade glioma showed more increased immunoreactivities to both anti-8-oxo-dG and anti-MTH1, compared with those of low-grade glioma ( Fig. 3A and 3B ). Statistical analyses revealed signi cant differences in immunoreactivities to both anti-8-oxo-dG and anti-MTH1 between high-grade and low-grade glioma (P < 0.05).
In 4 cases of medulloblastoma, all showed moderate or high immunoreactivities to both anti-8-oxo-dG and anti-MTH1 (Fig. 2G and 2H ).
Brain tumor from autopsy. As summarized in Table 1 , in 4 of 5 cases, brain tumor tissues were more intensively stained for both anti-8-oxo-dG and anti-MTH1 than were normal tissues in the same specimen ( Fig. 4A and  4B ). Statistical analyses revealed a signi cant increase in immunoreactivities for both anti-8-oxo-dG and anti-MTH1 in the tumors compared with those in the cerebral cortex (Table 2 , P < 0.05).
Discussion
It is generally accepted that ROS are involved in early events of carcinogenesis by causing premutagenic modi- cations in DNA and accumulation of 8-oxoguanine, which indicates the presence of oxidative stress. Oxidative DNA damage is important, not only in initiation of carcinogenesis, but also in its progression (Toyokuni et al., 1997) .
The main conclusion of the present study is that brain tumor tissues are exposed to severe oxidative stress, revealed by the presence of anti-8-oxo-dG when immunohistochemistry was used, and increase the capacity of defense mechanisms against such oxidative stress, revealed by MTH1-immunoreactivity. Furthermore, it is suggested that the grade of brain tumor is well correlated with the degree of oxidative stress. These results are an additional indication that oxidative stress may play a role in tumor progression.
Among the oxidative lesions of DNA, 8-oxoguanine, an oxidized form of guanine, is considered a major cause of mutagenesis by ROS (Tajiri et al., 1995; Boiteux and Radicella, 1999) . Previous studies have shown that the levels of 8-oxo-dG in DNA are elevated in tumor cells (Lee et Yamamoto et al., 1996) and that 8-oxo-dG is accumulated in their nuclei (Inoue et al., 1998; Kondo et al., 1999; Matsui et al., 1999) . High accumulations of 8-oxo-dG in DNA may play a causative role in carcinogenesis (Boiteux and Radicella, 1999; Floyd, 1990; Toyokuni et al., 1995) . In brain tumors, increased accumulation of 8-oxo-dG, based on data obtained by high-performance liquid chromatography with electrochemical detector (Nowak et al., 1999) and gas chromatography with mass spectrometry (Olinski et al., 1992) , has been reported. Detecting the presence of 8-oxo-dG in preparations of tumor DNA is possibly affected by oxidation during the extraction from frozen materials. Our preliminary study showed that 8-oxo-dG did not accumulate signi cantly in the paraf nembedded materials, whereas it was markedly increased in the specimens xed for a longer time with 10% formalin solution. Therefore, direct investigation of paraf n sections with a short xation time leads to more reliable study of 8-oxo-dG. In the present study, we examined the presence of 8-oxo-dG in brain tumor tissues immunohistochemically and con rmed that 8-oxo-dG is indeed accumulated in brain tumor cells, especially in their nuclei. Our results indicate that brain tumor tissues are exposed to severe oxidative stress that mostly affects nuclear DNA.
MTH1 is an enzyme that hydrolyzes oxidized purine nucleoside triphosphates, such as 8-oxo-dGTP and 2-hydroxy-dATP in the nucleotide pool, thereby reducing accumulation of such oxidized nucleotides in DNA (Fujikawa et al., 1999; Sakumi et al., 1993; Sekiguchi, 1996) . Recently, several studies revealed that the level of MTH1 mRNA is greatly increased in cancerous tissues, such as lung, renal cell, and breast tumors, compared with the adjacent normal tissues (Kennedy et al., 1998; Okamoto et al., 1996; Wani et al., 1998) . The human MTH1 gene encodes 7 different mRNAs formed by alternative initiation and splicing, and 4 different isoforms of MTH1 polypeptides (MTH1a to MTH1d) were identied in cultured human cells (Oda et al., 1997; . Thus, it is very important to address which isoform of MTH1 polypeptides is highly expressed in human cancerous tissues.
We have previously prepared anti-MTH1 antibodies that can be applied for detection of MTH1 protein on immunoblots and by immunohistochemistry as well (Kang et al., 1995; Kakuma et al., 1995) . Using this anti-MTH1, it was recently reported that expression of MTH1d, a major isoform of MTH1 polypeptides, is highly overexpressed in dopaminergic neurons of the sabstantia nigra in brain tissues derived from Parkinson's disease patients (Shimura-Miura et al., 1999) , suggesting that MTH1d expression is enhanced by the increased oxidative stress known to affect dopaminergic neurons in patients with Parkinson's.
In the present study, using anti-MTH1 in an immunoblotting analysis, we detected an overexpressed 18-kDa MTH1 polypeptide corresponding to the major isoform, MTH1d, in brain tumor tissues. Immunohistochemistry with the anti-MTH1 indicated that MTH1 protein was present in both nuclei and cytoplasm in 36 of 45 cases, and only in cytoplasm in 9 cases. In cultured human cells, MTH1d is present mainly in cytoplasm and some are present in mitochondria and nuclei (Kang et al., 1995) . Because the pool of dNTP for nuclear DNA replication is present mainly in the cytosol in human cells (Bestwick et al., 1982) , it seems likely that the MTH1 present in cytoplasm hydrolyzes 8-oxo-dGTP or 2-hydroxy-dATP generated in the nucleotide pool to prevent their misincorporation into DNA. Hence, increased accumulation of 8-oxo-dG in the nuclei of brain tumor cells indicates that there is a signi cantly higher level of oxidation of such nucleotides in the dNTP pool than in the adjacent normal tissues (P < 0.05). It is likely that the levels of oxidized nucleotides in the pool of tumor cells are beyond the hydrolyzing capacity of MTH1; thus, 8-oxo-dG was incorporated into nuclear DNA.
In tumor cells, increased oxidative stress may lead to accumulation of oxidized purine nucleoside triphosphates in the dNTP pool, which may trigger the enhanced expression of MTH1 and/or its translocation into nuclei.
Recently, Tanaka et al. (2000) identi ed a novel ribonucleotide reductase small subunit (p53R2), the expression of which is induced by p53. They hypothesized that p53R2 is likely to supply urgent precursors for DNA synthesis at the actual site of DNA repair within the damaged nuclei of arrested cells, because p53R2 translocates into nuclei after exposure of cells to DNA-damaging agents. It has been shown that a major classical ribonucleoside reductase complex locates mostly in cytoplasm and functions to supply precursors for replicative DNA synthesis. So the nuclear form of MTH1 may function to eliminate oxidized purine nucleotides from the precursor pool produced by p53R2 complex for repair replication, because there is severe oxidative stress resulting in an increase of 8-oxo-dG accumulation in tumor cells. Okamoto et al. (1996) suggested that the levels of MTH1 mRNA increase with the stage of disease. In contrast, Wani et al. (1998) found no signi cant association between MTH1 gene expression, tumor grade, and metastatic malignancy of breast tumors. Other studies found no correlation between clinical stage of cancer and 8-oxo-dG accumulation (Kondo et al., 1999; Okamoto et al., 1994) . On the other hand, 2 groups reported that levels of 8-oxo-dG in malignant tumors were different from those of benign tumors (Kondo et al., 1999; Musarrat et al., 1996) .
In the present study, we demonstrate that high-grade gliomas accumulate more 8-oxo-dG and express more MTH1 than do low-grade gliomas. Brain tumor samples ranged from benign to malignant tumors. Although we cannot show a highly quantitative correlation to clinical stages of malignant tumors, a signi cant qualitative difference between high-and low-grade gliomas was demonstrated (P < 0.05). This result suggests that an increase in oxidative stress induces the corresponding defensive mechanisms, producing higher levels of defensive mechanisms against 8-oxo-dG accumulation in highgrade gliomas than in low-grade gliomas, as previously suggested by Kennedy et al. (1998) . In addition, 18 of 19 high-grade gliomas showed hMTH1 expression in nuclei, whereas only 7 of 14 low-grade gliomas showed hMTH1 expression in nuclei. This result may also be related to tumor malignancy. Because few studies about hMTH1 expression in neoplasia have been reported, further studies are recommended to know its signi cance. Mutation of the TP53 gene is another factor that may alter cellular response to oxidative stress. However, what causes such increased oxidative stress in malignant cancer cells remains to be answered.
In medulloblastoma, as well as in high-grade glioma, all cases showed a moderate or high level of both 8-oxodG accumulation and MTH1 expression. These results suggest that undifferentiated brain tumors such as highgrade glioma and medulloblastoma are exposed to more oxidative stress than are differentiated brain tumors. 
